Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 21; no. 6; pp. 1385 - 1387
Main Authors Ferté, C., Besse, B., Dansin, E., Parent, F., Buisine, M.-P., Copin, M.-C., Penel, N., Soria, J.-C.
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 01.06.2010
Oxford University Press
Subjects
Adenocarcinoma - drug therapy
Adenocarcinoma - genetics
Adenocarcinoma - pathology
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Erlotinib Hydrochloride
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Medical sciences
Mutation - physiology
Neoplasm Metastasis
Pharmacology. Drug treatments
Pneumology
Proto-Oncogene Proteins - genetics
Proto-Oncogene Proteins p21(ras)
Quinazolines - therapeutic use
ras Proteins - genetics
Remission Induction
Time Factors
Tumors of the respiratory system and mediastinum
Antineoplastic agent
Quinazoline derivatives
Lung cancer
Metastasis
Bronchopulmonary adenocarcinoma
Bronchopulmonary
K ras Gene
Bronchus disease
Genetics
Advanced stage
Protein-tyrosine kinase
Protooncogene
Human
Lung disease
Enzyme
Tyrosine kinase inhibitor
Respiratory disease
Transferases
Enzyme inhibitor
Patient
Malignant tumor
Erlotinib
C-Onc gene
Mutation
Cancer
Online AccessGet full text

Cover

More Information
Bibliography:ark:/67375/HXZ-W3JZDD3W-8
istex:43078842B812683AE8DF57D03B164312215C6BBE
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 23
ObjectType-Review-2
ObjectType-Case Study-4
ObjectType-Report-3
ObjectType-Article-5
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdq153